{"id":167600,"date":"2026-07-24T10:04:57","date_gmt":"2026-07-24T04:34:57","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=167600"},"modified":"2026-07-24T10:04:59","modified_gmt":"2026-07-24T04:34:59","slug":"cipla-share-price-target-rs-1600-jpmorgan-overweight","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/cipla-share-price-target-rs-1600-jpmorgan-overweight\/","title":{"rendered":"Cipla Share Price Target Set at Rs 1,600 as JPMorgan Maintains Overweight Rating After Q1 Results"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>JPMorgan maintains overweight on Cipla, share price target Rs 1,600. Q1 revenue in line. EBITDA margin 16.7 percent, 75 bps below estimates. FY27 margin guidance of 18.5 to 20 percent retained.<\/em><\/p>\n<p>The Cipla share price target has been set at Rs 1,600 by JPMorgan, which maintained its overweight rating on the pharma major after the company&#8217;s Q1 FY27 results. The brokerage noted that <a href=\"https:\/\/univest.in\/stocks\/cipla\/cipla-ltd-share-price-today\">Cipla<\/a> delivered revenue in line with estimates, although the EBITDA margin of 16.7 percent missed expectations by 75 basis points.<\/p>\n<p>Despite the margin miss, JPMorgan&#8217;s conviction on the Cipla share price target rests on the company&#8217;s US launch pipeline and operating leverage, with management retaining its FY27 EBITDA margin guidance of 18.5 to 20 percent and asserting that margins have not normalised at current levels.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=cipla-jpmorgan-target-1600\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/cipla-share-price-target-rs-1600-jpmorgan-overweight\/#Cipla_Share_Price_Target_and_Q1_Highlights\" title=\"Cipla Share Price Target and Q1 Highlights\">Cipla Share Price Target and Q1 Highlights<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/cipla-share-price-target-rs-1600-jpmorgan-overweight\/#Why_JPMorgan_Backs_the_Cipla_Share_Price_Target\" title=\"Why JPMorgan Backs the Cipla Share Price Target\">Why JPMorgan Backs the Cipla Share Price Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/cipla-share-price-target-rs-1600-jpmorgan-overweight\/#Key_Catalysts_for_the_Cipla_Share_Price_Target\" title=\"Key Catalysts for the Cipla Share Price Target\">Key Catalysts for the Cipla Share Price Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/cipla-share-price-target-rs-1600-jpmorgan-overweight\/#Risks_to_the_Overweight_Call\" title=\"Risks to the Overweight Call\">Risks to the Overweight Call<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/cipla-share-price-target-rs-1600-jpmorgan-overweight\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/cipla-share-price-target-rs-1600-jpmorgan-overweight\/#Frequently_Asked_Questions_FAQs\" title=\"Frequently Asked Questions FAQs\">Frequently Asked Questions FAQs<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/cipla-share-price-target-rs-1600-jpmorgan-overweight\/#What_is_the_Cipla_share_price_target_from_JPMorgan\" title=\"What is the Cipla share price target from JPMorgan?\">What is the Cipla share price target from JPMorgan?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/cipla-share-price-target-rs-1600-jpmorgan-overweight\/#How_did_Cipla_perform_in_Q1_FY27\" title=\"How did Cipla perform in Q1 FY27?\">How did Cipla perform in Q1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/cipla-share-price-target-rs-1600-jpmorgan-overweight\/#Why_is_JPMorgan_overweight_on_Cipla\" title=\"Why is JPMorgan overweight on Cipla?\">Why is JPMorgan overweight on Cipla?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/cipla-share-price-target-rs-1600-jpmorgan-overweight\/#What_are_the_near_term_catalysts_for_Cipla\" title=\"What are the near term catalysts for Cipla?\">What are the near term catalysts for Cipla?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/cipla-share-price-target-rs-1600-jpmorgan-overweight\/#What_are_the_risks_to_the_Cipla_share_price_target\" title=\"What are the risks to the Cipla share price target?\">What are the risks to the Cipla share price target?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/cipla-share-price-target-rs-1600-jpmorgan-overweight\/#Should_investors_buy_Cipla_based_on_the_JPMorgan_target\" title=\"Should investors buy Cipla based on the JPMorgan target?\">Should investors buy Cipla based on the JPMorgan target?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Cipla_Share_Price_Target_and_Q1_Highlights\"><\/span><strong>Cipla Share Price Target and Q1 Highlights<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The key data points behind the JPMorgan call on the Cipla share price target are summarised below.<\/p>\n<table>\n<thead>\n<tr>\n<th>Parameter<\/th>\n<th>Detail<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Brokerage<\/td>\n<td>JPMorgan<\/td>\n<\/tr>\n<tr>\n<td>Rating<\/td>\n<td>Overweight (maintained)<\/td>\n<\/tr>\n<tr>\n<td>Cipla share price target<\/td>\n<td>Rs 1,600<\/td>\n<\/tr>\n<tr>\n<td>Q1 revenue<\/td>\n<td>In line with estimates<\/td>\n<\/tr>\n<tr>\n<td>Q1 EBITDA margin<\/td>\n<td>16.7 percent, 75 bps below estimates<\/td>\n<\/tr>\n<tr>\n<td>FY27 EBITDA margin guidance<\/td>\n<td>18.5 to 20 percent (retained)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Why_JPMorgan_Backs_the_Cipla_Share_Price_Target\"><\/span><strong>Why JPMorgan Backs the Cipla Share Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The investment case behind the Cipla share price target is driven by the US launch pipeline and operating leverage, according to the brokerage. Cipla has been building a portfolio of complex generics and respiratory products for the American market, where successful launches carry significantly higher margins than commoditised generics.<\/p>\n<p>Management&#8217;s statement that margins have not normalised suggests the 16.7 percent Q1 print reflects transitional costs rather than a structural reset. If the FY27 guidance of 18.5 to 20 percent holds, the margin trajectory alone implies meaningful earnings growth through the year.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Catalysts_for_the_Cipla_Share_Price_Target\"><\/span><strong>Key Catalysts for the Cipla Share Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>JPMorgan identifies near term catalysts that could move the stock toward the Cipla share price target of Rs 1,600. Product approvals from the US FDA top the list, since each complex generic clearance adds a fresh revenue stream.<\/p>\n<p>The outcome of the re-inspection at the Indore facility is the second trigger. A clean report would de-risk supplies to the US market and remove a compliance overhang, while an adverse outcome would delay pipeline monetisation. Investors in the pharma space watch such inspection outcomes closely because they historically drive sharp single day moves.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Screen pharma stocks by margin and growth on the Univest Screener<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Risks_to_the_Overweight_Call\"><\/span><strong>Risks to the Overweight Call<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The 75 basis point margin miss in Q1 is a reminder that execution risk to the Cipla share price target is real. Price erosion in the US generics market, delays in approvals, adverse inspection findings and currency volatility could all defer the margin recovery that underpins the Rs 1,600 valuation.<\/p>\n<p>Sector dynamics also matter. The <a href=\"https:\/\/univest.in\/indices\/nifty-pharma\/nifty-pharma-share-price-today\">Nifty Pharma<\/a> index has outperformed in risk off phases as investors rotate into defensives, and with broader markets under pressure from rising US yields, pharma&#8217;s defensive appeal could support the stock even in weak tape.<\/p>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track the Cipla share price and brokerage updates live.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>JPMorgan has maintained its overweight stance with a Cipla share price target of Rs 1,600, looking past a 75 basis point Q1 margin miss to the US launch pipeline, operating leverage and retained FY27 margin guidance of 18.5 to 20 percent. Product approvals and the Indore re-inspection outcome are the catalysts to watch. Investors should evaluate the risks and consult a SEBI registered advisor before acting on brokerage targets.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_FAQs\"><\/span><strong>Frequently Asked Questions FAQs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Cipla_share_price_target_from_JPMorgan\"><\/span><strong>What is the Cipla share price target from JPMorgan?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> JPMorgan has set a Cipla share price target of Rs 1,600 and maintained its overweight rating on the stock after the company&#8217;s Q1 FY27 results.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_did_Cipla_perform_in_Q1_FY27\"><\/span><strong>How did Cipla perform in Q1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Cipla reported revenue in line with estimates, but its EBITDA margin of 16.7 percent missed expectations by 75 basis points. Management said margins have not normalised and retained FY27 guidance of 18.5 to 20 percent.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_is_JPMorgan_overweight_on_Cipla\"><\/span><strong>Why is JPMorgan overweight on Cipla?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The investment case is driven by Cipla&#8217;s US launch pipeline of complex generics and respiratory products, and by operating leverage that should lift margins toward the guided 18.5 to 20 percent band through FY27.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_near_term_catalysts_for_Cipla\"><\/span><strong>What are the near term catalysts for Cipla?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Near term catalysts include US FDA product approvals and the outcome of the re-inspection at the Indore facility. A favourable inspection result would de-risk US supplies and remove a compliance overhang.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_risks_to_the_Cipla_share_price_target\"><\/span><strong>What are the risks to the Cipla share price target?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Key risks include price erosion in US generics, delays in product approvals, adverse regulatory inspection findings, and any failure to deliver the guided margin recovery from the 16.7 percent Q1 level.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Should_investors_buy_Cipla_based_on_the_JPMorgan_target\"><\/span><strong>Should investors buy Cipla based on the JPMorgan target?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Brokerage targets are opinions, not guarantees. Investors should weigh the catalysts against execution risks, consider their own horizon, and consult a SEBI registered advisor before making investment decisions.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>JPMorgan has maintained an overweight rating on Cipla with a share price target of Rs 1,600 after Q1 results, citing the US launch pipeline, operating leverage and retained FY27 margin guidance.<\/p>\n","protected":false},"author":28,"featured_media":167681,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-167600","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1784867701:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["78"],"rank_math_title":["Cipla Share Price Target Rs 1,600: JPMorgan Stays Overweight"],"rank_math_description":["JPMorgan maintains overweight with a Cipla share price target of Rs 1,600 after Q1 results, citing the US launch pipeline and operating leverage. Details inside."],"rank_math_focus_keyword":["Cipla share price target"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_thumbnail_id":["167681"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["30121"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/07\/Cipla-Share-Price-Target.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/167600","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=167600"}],"version-history":[{"count":2,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/167600\/revisions"}],"predecessor-version":[{"id":167683,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/167600\/revisions\/167683"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/167681"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=167600"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=167600"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=167600"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}